Phase IB Trial of Niraparib and TSR-042 in Patients With BRCA-Mutated Breast, Pancreas or Ovary Cancer
The purpose of this phase Ib trial is to evaluate the safety and efficacy of niraparib and dostarlimab (TSR-042) in patients with unresectable or metastatic BRCA-mutated select cancers, including pancreatic cancer.
Study ID: RG1005140
Trial Phase: Phase I
Trial Sponsor: GlaxoSmithKline, University of Washington
Therapies Used in This Trial: Niraparib, Dostarlimab